Special Issues/Analytical Biomaterials/Review Article
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Ten Years of Lateral Flow Immunoassay Technique Applications: Trends, Challenges and Future Perspectives
sensors Review Ten Years of Lateral Flow Immunoassay Technique Applications: Trends, Challenges and Future Perspectives Fabio Di Nardo * , Matteo Chiarello , Simone Cavalera , Claudio Baggiani and Laura Anfossi Department of Chemistry, University of Torino, 10125 Torino, Italy; [email protected] (M.C.); [email protected] (S.C.); [email protected] (C.B.); [email protected] (L.A.) * Correspondence: [email protected] Abstract: The Lateral Flow Immunoassay (LFIA) is by far one of the most successful analytical platforms to perform the on-site detection of target substances. LFIA can be considered as a sort of lab-in-a-hand and, together with other point-of-need tests, has represented a paradigm shift from sample-to-lab to lab-to-sample aiming to improve decision making and turnaround time. The features of LFIAs made them a very attractive tool in clinical diagnostic where they can improve patient care by enabling more prompt diagnosis and treatment decisions. The rapidity, simplicity, relative cost-effectiveness, and the possibility to be used by nonskilled personnel contributed to the wide acceptance of LFIAs. As a consequence, from the detection of molecules, organisms, and (bio)markers for clinical purposes, the LFIA application has been rapidly extended to other fields, including food and feed safety, veterinary medicine, environmental control, and many others. This review aims to provide readers with a 10-years overview of applications, outlining the trends for the main application fields and the relative compounded annual growth rates. Moreover, future perspectives and challenges are discussed. Citation: Di Nardo, F.; Chiarello, M.; Cavalera, S.; Baggiani, C.; Anfossi, L. -
Development of a Platform for Lateral Flow Test Devices with the Capability of Using Multiple Fluids
University of Rhode Island DigitalCommons@URI Open Access Master's Theses 2013 Development of a Platform for Lateral Flow Test Devices with the Capability of Using Multiple Fluids Wilke Föllscher University of Rhode Island, [email protected] Follow this and additional works at: https://digitalcommons.uri.edu/theses Recommended Citation Föllscher, Wilke, "Development of a Platform for Lateral Flow Test Devices with the Capability of Using Multiple Fluids" (2013). Open Access Master's Theses. Paper 124. https://digitalcommons.uri.edu/theses/124 This Thesis is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Open Access Master's Theses by an authorized administrator of DigitalCommons@URI. For more information, please contact [email protected]. DEVELOPMENT OF A PLATFORM FOR LATERAL FLOW TEST DEVICES WITH THE CAPABILITY OF USING MULTIPLE FLUIDS BY WILKE FÖLLSCHER A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF SCIENCE IN MECHANICAL ENGINEERING AND APPLIED MECHANICS UNIVERSITY OF RHODE ISLAND 2013 MASTER OF SCIENCE IN MECHANICAL ENGINEERING OF WILKE FÖLLSCHER APPROVED: Thesis Committee: Major Professor Mohammad Faghri Constantine Anagnostopoulos Keykavous Parang Nasser H. Zawia DEAN OF THE GRADUATE SCHOOL UNIVERSITY OF RHODE ISLAND 2013 ABSTRACT This study presents the development of a 3-fluid microfluidic device for the application in immunoassays. The test uses a microfluidic valve in order to sequentially load the reagents autonomously onto the detection area after adding the sample. The development of the multi-fluid circuit allows the application of an enzyme-linked assay in a lateral flow device as to provide with an improved sensitivity compared to strip tests available on the market. -
Advances in Addressing Technical Challenges of Point-Of-Care Diagnostics in Resource-Limited Settings
Expert Review of Molecular Diagnostics ISSN: 1473-7159 (Print) 1744-8352 (Online) Journal homepage: http://www.tandfonline.com/loi/iero20 Advances in addressing technical challenges of point-of-care diagnostics in resource-limited settings ShuQi Wang, Mark A Lifson, Fatih Inci, Li-Guo Liang, Ye-Feng Sheng & Utkan Demirci To cite this article: ShuQi Wang, Mark A Lifson, Fatih Inci, Li-Guo Liang, Ye-Feng Sheng & Utkan Demirci (2016): Advances in addressing technical challenges of point-of-care diagnostics in resource-limited settings, Expert Review of Molecular Diagnostics, DOI: 10.1586/14737159.2016.1142877 To link to this article: http://dx.doi.org/10.1586/14737159.2016.1142877 Accepted author version posted online: 16 Jan 2016. Submit your article to this journal Article views: 41 View related articles View Crossmark data Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=iero20 Download by: [171.67.216.21] Date: 15 February 2016, At: 17:17 Publisher: Taylor & Francis Journal: Expert Review of Molecular Diagnostics DOI: 10.1586/14737159.2016.1142877 Review Expert Review of Molecular Diagnostics Title: Advances in addressing technical challenges of point-of-care diagnostics in resource- limited settings Running title: POC diagnostics in resource-limited settings Authors: ShuQi Wang 1, 2, 3, 4, *, Mark A Lifson 4, Fatih Inci 4, Li-Guo Liang 1, 2, 3, Ye-Feng Sheng 1, 2, 3, 4,, Utkan Demirci 4, * 1. State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China 2. Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, China 3. -
Oleandrin-Mediated Inhibition of Human Tumor Cell Proliferation: Importance of Na,K-Atpase Α Subunits As Drug Targets
Published OnlineFirst August 11, 2009; DOI: 10.1158/1535-7163.MCT-08-1085 2319 Oleandrin-mediated inhibition of human tumor cell proliferation: Importance of Na,K-ATPase α subunits as drug targets Peiying Yang,1 David G. Menter,2 relatively higher expression of α3 with the limited expres- Carrie Cartwright,1 Diana Chan,1 Susan Dixon,1 sion of α1 may help predict which human tumors are likely Milind Suraokar,2 Gabriela Mendoza,2 to be responsive to treatment with potent lipid-soluble car- Norma Llansa,2 and Robert A. Newman1 diac glycosides such as oleandrin. [Mol Cancer Ther 2009;8(8):2319–28] Departments of 1Experimental Therapeutics and 2Thoracic/Head and Neck Medical Oncology and Clinical Cancer Prevention, The University of Texas, M. D. Anderson Cancer, Houston, Texas Introduction Cardiac glycosides are a class of compounds used to treat Abstract congestive heart failure by increasing myocardial contractile Cardiac glycosides such as oleandrin are known to inhibit force (1). Oleandrin is a cardiac glycoside derived from the Na,K-ATPase pump, resulting in a consequent increase Nerium oleander, which has been used for many years in in calcium influx in heart muscle. Here, we investigated Russia and China for this purpose. In contrast to its use the effect of oleandrin on the growth of human and mouse for the treatment of heart failure, preclinical and retrospec- cancer cells in relation to Na,K-ATPase subunits. Olean- tive patient data suggest that cardiac glycosides (e.g., digox- drin treatment resulted in selective inhibition of human in, digitoxin, ouabain, and oleandrin), may reduce the cancer cell growth but not rodent cell proliferation, which growth of various cancers including breast, lung, prostate, corresponded to the relative level of Na,K-ATPase α3 sub- and leukemia (2–7). -
Oleander and Datura Poisoning: an Update Vijay V Pillay1, Anu Sasidharan2
INVITED ARTICLE Oleander and Datura Poisoning: An Update Vijay V Pillay1, Anu Sasidharan2 ABSTRACT India has a very high incidence of poisoning. While most cases are due to chemicals or drugs or envenomation by venomous creatures, a significant proportion also results from consumption or exposure to toxic plants or plant parts or products. The exact nature of plant poisoning varies from region to region, but certain plants are almost ubiquitous in distribution, and among these, Oleander and Datura are the prime examples. These plants are commonly encountered in almost all parts of India. While one is a wild shrub (Datura) that proliferates in the countryside and by roadsides, and the other (Oleander) is a garden plant that features in many homes. Incidents of poisoning from these plants are therefore not uncommon and may be the result of accidental exposure or deliberate, suicidal ingestion of the toxic parts. An attempt has been made to review the management principles with regard to toxicity of these plants and survey the literature in order to highlight current concepts in the treatment of poisoning resulting from both plants. Keywords: Cerbera, Datura, Nerium, Oleander, Plant poison, Thevetia. Indian Journal of Critical Care Medicine (2019): 10.5005/jp-journals-10071-23302 INTRODUCTION 1Department of Forensic Medicine and Toxicology, Poison Control India being a tropical country is host to a rich and varied Centre, Amrita School of Medicine, Amrita Vishwa Vidyapeetham, flora encompassing thousands of plants; and while most are Kochi, Kerala, India nonpoisonous, a significant few possess toxic properties of varying 2Department of Forensic Medicine and Toxicology, Forensic Pathology degree. -
Scalable Manufacturing Methods for Biomedical Microfluidics
SCALABLE MANUFACTURING METHODS FOR BIOMEDICAL MICROFLUIDICS A Dissertation Presented By David Ignatius Walsh III To The Department of Bioengineering in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the field of Bioengineering Northeastern University Boston, Massachusetts May 2016 ACKNOWLEDGEMENTS The adventure that had led to the culmination of this work has only been possible with the unwavering support of mentors, colleagues, friends, and family. First, I would like to express my deepest gratitude to my advisor, Dr. Shashi Murthy. Your ever-present, unyielding support, dependability, and never-ending supply of advice has made this PhD story so successful. And to my committee, Dr. Mark Niedre and Dr. Edgar Goluch, thank you for not only your technical advice, but also your time and patience. I would also like to thank all of my mentors for their support - Dr. Gregory Sommer for igniting my passion in biomedical microfluidics, Dr. Aman Russom for giving me an appreciation for the global nature of research, and Dr. Peter Carr for instilling the importance of believing in the work you do. The time I have spent with all of you has been priceless, and will enable me to one day pass along these lessons to new researchers. A thank you to all of my current and past lab members - Beili, Dayo, Mariana, Dwayne, Adam, Sean, Tanya, Brian, Sanjin, and Brad; as well as labmates from Sweden – Sahar, Indra, Harisha, Mary, Hasim, Nilay, Frida, and Zenib; and colleagues from MIT- Lincoln – David, Matt, Scott, Johanna, Jim, Carlos, Todd, and Rafmag. I have greatly appreciated all of your advice and listening ears to my research problems. -
Clinical Significance of P‑Class Pumps in Cancer (Review)
ONCOLOGY LETTERS 22: 658, 2021 Clinical significance of P‑class pumps in cancer (Review) SOPHIA C. THEMISTOCLEOUS1*, ANDREAS YIALLOURIS1*, CONSTANTINOS TSIOUTIS1, APOSTOLOS ZARAVINOS2,3, ELIZABETH O. JOHNSON1 and IOANNIS PATRIKIOS1 1Department of Medicine, School of Medicine; 2Department of Life Sciences, School of Sciences, European University Cyprus, 2404 Nicosia, Cyprus; 3College of Medicine, Member of Qatar University Health, Qatar University, 2713 Doha, Qatar Received January 25, 2021; Accepted Apri 12, 2021 DOI: 10.3892/ol.2021.12919 Abstract. P‑class pumps are specific ion transporters involved Contents in maintaining intracellular/extracellular ion homeostasis, gene transcription, and cell proliferation and migration in all 1. Introduction eukaryotic cells. The present review aimed to evaluate the 2. Methodology role of P‑type pumps [Na+/K+ ATPase (NKA), H+/K+ ATPase 3. NKA (HKA) and Ca2+‑ATPase] in cancer cells across three fronts, 4. SERCA pump namely structure, function and genetic expression. It has 5. HKA been shown that administration of specific P‑class pumps 6. Clinical studies of P‑class pump modulators inhibitors can have different effects by: i) Altering pump func‑ 7. Concluding remarks and future perspectives tion; ii) inhibiting cell proliferation; iii) inducing apoptosis; iv) modifying metabolic pathways; and v) induce sensitivity to chemotherapy and lead to antitumor effects. For example, 1. Introduction the NKA β2 subunit can be downregulated by gemcitabine, resulting in increased apoptosis of cancer cells. The sarco‑ The movement of ions across a biological membrane is a endoplasmic reticulum calcium ATPase can be inhibited by crucial physiological process necessary for maintaining thapsigargin resulting in decreased prostate tumor volume, cellular homeostasis. -
In Vitro and in Vivo Neuroprotective Activity of the Cardiac Glycoside
JOURNAL OF NEUROCHEMISTRY | 2011 | 119 | 805–814 doi: 10.1111/j.1471-4159.2011.07439.x *Center for Drug Discovery and Department of Neurobiology, Duke University Medical Center, Durham, North Carolina, USA Department of Experimental Therapeutics, The University of Texas, M. D. Anderson Cancer Center, Houston, Texas, USA Abstract tained for several hours of delay of administration after oxygen The principal active constituent of the botanical drug candi- and glucose deprivation treatment. We provide evidence that date PBI-05204, a supercritical CO2 extract of Nerium the neuroprotective activity of PBI-05204 is mediated through oleander, is the cardiac glycoside oleandrin. PBI-05204 shows oleandrin and/or other cardiac glycoside constituents, but that potent anticancer activity and is currently in phase I clinical additional, non-cardiac glycoside components of PBI-05204 trial as a treatment for patients with solid tumors. We have may also contribute to the observed neuroprotective activity. previously shown that neriifolin, which is structurally related to Finally, we show directly that both oleandrin and the protective oleandrin, provides robust neuroprotection in brain slice and activity of PBI-05204 are blood brain barrier penetrant in a whole animal models of ischemic injury. However, neriifolin novel model for in vivo neuroprotection. Together, these itself is not a suitable drug development candidate and the findings suggest clinical potential for PBI-05204 in the treat- FDA-approved cardiac glycoside digoxin does not cross the ment of ischemic stroke and prevention of associated neuro- blood–brain barrier. We report here that both oleandrin as well nal death. as the full PBI-05204 extract can also provide significant Keywords: biolistics, brain slice, cardiac glycoside, Na+,K+- neuroprotection to neural tissues damaged by oxygen and ATPase, neuroprotection. -
Lateral Flow Immunoassays with Fluorescent Reporter Technologies
ANNALES UNIVERSITATIS TURKUENSIS ANNALES UNIVERSITATIS A I 575 Etvi Juntunen Etvi LATERAL FLOW IMMUNOASSAYS WITH FLUORESCENT REPORTER TECHNOLOGIES Etvi Juntunen ISBN 978-951-29-7126-8 (PRINT) , Finland 2018 Turku Painosalama Oy, ISBN 978-951-29-7127-5 (PDF) TURUN YLIOPISTON JULKAISUJA – ANNALES UNIVERSITATIS TURKUENSIS ISSN 0082-7002 (PRINT) | ISSN 2343-3175 (ONLINE) Sarja – ser. AI osa – tom. 575 | Astronomica – Chemica – Physica – Mathematica | Turku 2018 LATERAL FLOW IMMUNOASSAYS WITH FLUORESCENT REPORTER TECHNOLOGIES Etvi Juntunen TURUN YLIOPISTON JULKAISUJA – ANNALES UNIVERSITATIS TURKUENSIS Sarja - ser. A I osa - tom. 575 | Astronomica - Chemica - Physica - Mathematica | Turku 2018 University of Turku Faculty of Science and Engineering Department of Biochemistry Molecular Biotechnology and Diagnostics Doctoral Programme in Molecular Life Sciences Supervised by Professor Kim Pettersson, PhD Professor Tero Soukka, PhD Department of Biochemistry Department of Biochemistry Molecular Biotechnology and Diagnostics Molecular Biotechnology and Diagnostics University of Turku University of Turku Turku, Finland Turku, Finland Reviewed by Adjunct Professor Senior scientist Petri Ihalainen, PhD Aart van Amerongen, PhD MetGen Oy Wageningen University & Research Kaarina, Finland Wageningen, Netherlands Opponent Professor Richard O’Kennedy, Ph.D. Vice president for research Hamad Bin Khalifa University Doha, Qatar Cover image by author The originality of this thesis has been checked in accordance with the University of Turku quality assurance system using the Turnitin OriginalityCheck service. ISBN 978-951-29-7126-8 (PRINT) ISBN 978-951-29-7127-5 (PDF) ISSN 0082-7002 (PRINT) ISSN 2343-3175 (ONLINE) Painosalama Oy - Turku, Finland 2017 “If you hit a wrong note, it's the next note that you play that determines if its's good or bad.” –Miles Davis Contents CONTENTS List of original publications ......................................................................................... -
Oleandrin: a Cardiac Glycosides with Potent Cytotoxicity
PHCOG REV. REVIEW ARTICLE Oleandrin: A cardiac glycosides with potent cytotoxicity Arvind Kumar, Tanmoy De, Amrita Mishra, Arun K. Mishra Department of Pharmaceutical Chemistry, Central Facility of Instrumentation, School of Pharmaceutical Sciences, IFTM University, Lodhipur, Rajput, Moradabad, Uttar Pradesh, India Submitted: 19-05-2013 Revised: 29-05-2013 Published: **-**-**** ABSTRACT Cardiac glycosides are used in the treatment of congestive heart failure and arrhythmia. Current trend shows use of some cardiac glycosides in the treatment of proliferative diseases, which includes cancer. Nerium oleander L. is an important Chinese folk medicine having well proven cardio protective and cytotoxic effect. Oleandrin (a toxic cardiac glycoside of N. oleander L.) inhibits the activity of nuclear factor kappa‑light‑chain‑enhancer of activated B chain (NF‑κB) in various cultured cell lines (U937, CaOV3, human epithelial cells and T cells) as well as it induces programmed cell death in PC3 cell line culture. The mechanism of action includes improved cellular export of fibroblast growth factor‑2, induction of apoptosis through Fas gene expression in tumor cells, formation of superoxide radicals that cause tumor cell injury through mitochondrial disruption, inhibition of interleukin‑8 that mediates tumorigenesis and induction of tumor cell autophagy. The present review focuses the applicability of oleandrin in cancer treatment and concerned future perspective in the area. Key words: Cardiac glycosides, cytotoxicity, oleandrin INTRODUCTION the toad genus Bufo that contains bufadienolide glycosides, the suffix-adien‑that refers to the two double bonds in the Cardiac glycosides are used in the treatment of congestive lactone ring and the ending-olide that denotes the lactone heart failure (CHF) and cardiac arrhythmia. -
Guide to Lateral Flow Immunoassays
Guide to Lateral Flow Immunoassays Innova Biosciences Guide Lateral flow immunoassays Components, process, assay formats and nanoparticles Innova Biosciences Ltd. Babraham Research Campus, Cambridge, UK, CB22 3AT +44 (0)1223 661000 [email protected] A guide to lateral flow immunoassays | 2 Contents 1. Evolution of lateral flow immunoassays 2. Immunoassays 3. Lateral flow immunoassays 3.1 The sample application pad 3.2 The conjugate release pad 3.3 The detection reagent 3.3.1 The antibody 3.3.2 The detection moiety 3.4 The membrane 3.5 The wicking pad 3.6 The plastic cassette 4. Process options 5. Assay formats 6. Advantages and disadvantages of lateral flow immunoassays 7. Nanoparticles for lateral flow immunoassays 8. Custom services from Innova Biosciences A guide to lateral flow immunoassays | 3 1. Evolution of lateral flow immunoassays Lateral flow immunoassays are a well-established and extremely versatile technology that can be applied to a wide variety of diagnostic applications. Since their inception in the late 1980s a huge range of lateral flow immunoassays have been launched, with the global lateral flow immunoassay market expected to be worth approximately $6 billion by 2020. Lateral flow immunoassays are widely used in hospitals and clinical laboratories, as well as in veterinary medicine, in environmental assessment, and for safety testing during food production. Due to the low development costs and the relative ease of production, this list of applications continues to grow. The technology on which lateral flow immunoassays are based was derived from the work of Singer and Plotz who, in 1956, developed a latex agglutination assay to diagnose rheumatoid arthritis. -
Evaluating the Cancer Therapeutic Potential of Cardiac Glycosides
Hindawi Publishing Corporation BioMed Research International Volume 2014, Article ID 794930, 9 pages http://dx.doi.org/10.1155/2014/794930 Review Article Evaluating the Cancer Therapeutic Potential of Cardiac Glycosides José Manuel Calderón-Montaño,1 Estefanía Burgos-Morón,1 Manuel Luis Orta,2 Dolores Maldonado-Navas,1 Irene García-Domínguez,1 and Miguel López-Lázaro1 1 Department of Pharmacology, Faculty of Pharmacy, University of Seville, 41012 Seville, Spain 2 DepartmentofCellBiology,FacultyofBiology,UniversityofSeville,Spain Correspondence should be addressed to Miguel Lopez-L´ azaro;´ [email protected] Received 27 February 2014; Revised 25 April 2014; Accepted 28 April 2014; Published 8 May 2014 Academic Editor: Gautam Sethi Copyright © 2014 Jose´ Manuel Calderon-Monta´ no˜ et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Cardiac glycosides, also known as cardiotonic steroids, are a group of natural products that share a steroid-like structure with an + + unsaturated lactone ring and the ability to induce cardiotonic effects mediated by a selective inhibition of the Na /K -ATPase. Cardiac glycosides have been used for many years in the treatment of cardiac congestion and some types of cardiac arrhythmias. Recent data suggest that cardiac glycosides may also be useful in the treatment of cancer. These compounds typically inhibit cancer cell proliferation at nanomolar concentrations, and recent high-throughput screenings of drug libraries have therefore identified cardiac glycosides as potent inhibitors of cancer cell growth. Cardiac glycosides can also block tumor growth in rodent models, which further supports the idea that they have potential for cancer therapy.